To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...

GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.

GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...

A Trinity Life Sciences report found that more pharma product launches were successful in 2023 than the year before. Here are ...

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...